Compare CPZ & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPZ | AARD |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.4M | 297.2M |
| IPO Year | N/A | 2025 |
| Metric | CPZ | AARD |
|---|---|---|
| Price | $15.02 | $15.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.11 |
| AVG Volume (30 Days) | 63.0K | ★ 214.6K |
| Earning Date | 01-01-0001 | 02-14-2026 |
| Dividend Yield | ★ 11.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.17 | $4.88 |
| 52 Week High | $16.11 | $19.58 |
| Indicator | CPZ | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 64.95 |
| Support Level | $15.05 | $14.25 |
| Resistance Level | $15.28 | $16.00 |
| Average True Range (ATR) | 0.16 | 0.93 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 70.82 | 82.00 |
Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.